Gabapentin structure
|
Common Name | Gabapentin | ||
---|---|---|---|---|
CAS Number | 60142-96-3 | Molecular Weight | 171.237 | |
Density | 1.1±0.1 g/cm3 | Boiling Point | 314.4±15.0 °C at 760 mmHg | |
Molecular Formula | C9H17NO2 | Melting Point | 162°C | |
MSDS | Chinese USA | Flash Point | 144.0±20.4 °C | |
Symbol |
GHS07, GHS08 |
Signal Word | Danger |
Use of GabapentinGabapentin (Neurontin) is a pharmaceutical drug, specifically a GABA analog. It was originally developed to treat epilepsy, and currently is also used to relieve neuropathic pain.IC50 Value: 140 nM (α2δ subunit of calcium channel) [1]Target: Calcium Channelin vitro: Gabapentin, baclofen and CGP 44532 all reduced the electrically stimulated release of [3H]glutamic acid (IC50=20 microM, 0.8 microM and 2 microM, respectively). Gabapentin was without effect on the release of [3H]GABA, whilst baclofen (IC50=8 microM) and CGP 44532 (IC50=1 microM) inhibited [3H]GABA release [2]. A large inhibition of calcium currents by gabapentin was observed in pyramidal neocortical cells (up to 34%). Significantly, the gabapentin-mediated inhibition of calcium currents saturated at particularly low concentrations (around 10 microM), at least in neocortical neurons (IC50 about 4 microM) [3].in vivo: Gabapentin produced an anti-allodynic effect over the 7-day period, reducing the expression of pro-inflammatory cytokines but increasing the expression of IL-10 (TNF-α, 316.0 ± 69.7 pg/mL vs 88.8 ± 24.4 pg/mL; IL-1β, 1,212.9 ± 104.5 vs 577.4 ± 97.1 pg/mL; IL-6, 254.0 ± 64.8 pg/mL vs 125.5 ± 44.1 pg/mL; IL-10, 532.1 ± 78.7 pg/mL vs 918.9 ± 63.1 pg/mL). The suppressive effect of gabapentin on pro-inflammatory cytokine expression was partially blocked by the anti-IL-10 antibody [4].Toxicity: No new safety signals or adverse event trends relating to GEn exposure were identified [5].Clinical trial: N/A |
Name | Gabapentin |
---|---|
Synonym | More Synonyms |
Description | Gabapentin (Neurontin) is a pharmaceutical drug, specifically a GABA analog. It was originally developed to treat epilepsy, and currently is also used to relieve neuropathic pain.IC50 Value: 140 nM (α2δ subunit of calcium channel) [1]Target: Calcium Channelin vitro: Gabapentin, baclofen and CGP 44532 all reduced the electrically stimulated release of [3H]glutamic acid (IC50=20 microM, 0.8 microM and 2 microM, respectively). Gabapentin was without effect on the release of [3H]GABA, whilst baclofen (IC50=8 microM) and CGP 44532 (IC50=1 microM) inhibited [3H]GABA release [2]. A large inhibition of calcium currents by gabapentin was observed in pyramidal neocortical cells (up to 34%). Significantly, the gabapentin-mediated inhibition of calcium currents saturated at particularly low concentrations (around 10 microM), at least in neocortical neurons (IC50 about 4 microM) [3].in vivo: Gabapentin produced an anti-allodynic effect over the 7-day period, reducing the expression of pro-inflammatory cytokines but increasing the expression of IL-10 (TNF-α, 316.0 ± 69.7 pg/mL vs 88.8 ± 24.4 pg/mL; IL-1β, 1,212.9 ± 104.5 vs 577.4 ± 97.1 pg/mL; IL-6, 254.0 ± 64.8 pg/mL vs 125.5 ± 44.1 pg/mL; IL-10, 532.1 ± 78.7 pg/mL vs 918.9 ± 63.1 pg/mL). The suppressive effect of gabapentin on pro-inflammatory cytokine expression was partially blocked by the anti-IL-10 antibody [4].Toxicity: No new safety signals or adverse event trends relating to GEn exposure were identified [5].Clinical trial: N/A |
---|---|
Related Catalog | |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 314.4±15.0 °C at 760 mmHg |
Melting Point | 162°C |
Molecular Formula | C9H17NO2 |
Molecular Weight | 171.237 |
Flash Point | 144.0±20.4 °C |
Exact Mass | 171.125931 |
PSA | 63.32000 |
LogP | 1.19 |
Vapour Pressure | 0.0±1.4 mmHg at 25°C |
Index of Refraction | 1.489 |
Storage condition | Desiccate at +4°C |
Water Solubility | H2O: 10 mg/mL |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS07, GHS08 |
---|---|
Signal Word | Danger |
Hazard Statements | H315-H319-H335-H360 |
Precautionary Statements | P201-P261-P305 + P351 + P338-P308 + P313 |
Personal Protective Equipment | Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
Hazard Codes | T |
Risk Phrases | R61 |
Safety Phrases | S53-S26-S36/37/39-S45 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
RTECS | GU6496000 |
HS Code | 2922499990 |
Precursor 8 | |
---|---|
DownStream 8 | |
HS Code | 2922499990 |
---|---|
Summary | HS:2922499990 other amino-acids, other than those containing more than one kind of oxygen function, and their esters; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) MFN tariff:6.5% General tariff:30.0% |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
J. Sci. Ind. Res. 65(10) , 808, (2006) Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI typ... |
|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Chem. Res. Toxicol. 23 , 1215-22, (2010) Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals ... |
|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Drug Metab. Dispos. 38 , 2302-8, (2010) Drug-induced liver injury (DILI) is one of the most important reasons for drug development failure at both preapproval and postapproval stages. There has been increased interest in developing predicti... |
Gabapetin |
Neurontin |
1-(Aminomethyl)-cyclohexaneacetic acid |
2-[1-(aminomethyl)cyclohexyl]acetic acid |
Cyclohexaneacetic acid, 1-(aminomethyl)- |
GABAPENTINE |
GABAPENTIN |
Gabapentin hydrochloride |
2-[(aminomethyl)cyclohexyl]acetic acid |
1-(aminomethyl)cyclohexaneacetic acid |
MFCD00865286 |
2-(1-(aminomethyl)cyclohexyl)acetic acid |
EINECS 262-076-3 |
Gababentin |
[1-(Aminomethyl)cyclohexyl]acetic acid |
Gabapentin HCl |